My role is to represent Health Canada. It's not the role of Health Canada to do that; the role is to provide the information effectively. Then, at the interface with the patient, that decision has to be made, and there are many considerations in that regarding, including patient tolerance, side effects, their health, economics—it's all there. So I wouldn't say that one is better than the other.
That's why we have organizations, such as CATMAT, that can sit down.... It takes a number of experts to sit together and consider it and then put out the recommendations. I wouldn't say that Health Canada has a best drug to recommend; its role is to explain the evidence around each product. Then, one of the uses of practice guidelines is that they inform practitioners about what the considerations of a given illness are, what products are available, and what you need to understand before you choose one.
It wouldn't be fair to say that one is better than the other.